A Phase 1-2 Pharmacokinetic Guided Dose-Escalation And Dose-Confirmation Study Of ASTX727, A Combination Of The Oral Cytidine Deaminase Inhibitor (Cdai) E7727 With Oral Decitabine In Subjects With Myelodysplastic Syndromes (MDS)